CTRI/2016/06/006986
Recruiting
未知
In metastatic prostate cancer requiring bilateral orchidectomy, is the satisfaction and genital perception following subcapsular approach superior to extracapsular approach?
Institutional Internal Fluid Research Funding0 sites70 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- Metastatic Prostate Cancer
- Sponsor
- Institutional Internal Fluid Research Funding
- Enrollment
- 70
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All patients with newly diagnosed metastatic prostate cancer willing for surgical castration i.e orchiectomy, with or without Channel TURP
Exclusion Criteria
- •Patients with Bleeding disorder or Uncorrected coagulopathy, and Psychiatric problems
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Radionuclide therapy using Lutetium-177 prostate specific membrane antigen (PSMA): a pilot study in men with castrate-resistant prostate cancer (LuPSMA trial)Prostate CancerCancer - ProstateACTRN12615000912583Peter MacCallum Cancer Centre30
Active, not recruiting
Phase 1
Response evaluation with 68Ga-PSMA PET of metastatic prostate cancer castration resistant patients in treatment with 223RaCl2Patients mCRPC eligible to treatment with 223RaCl2MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10005993Term: Bone metastasesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10036223Term: Positron emission tomographySystem Organ Class: 100000004848MedDRA version: 21.1Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-001395-38-ITAZIENDA USL DELLA VALLE D'AOSTA50
Active, not recruiting
Phase 2
A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate CancerMetastatic Hormone-sensitive Prostate CancerNCT03879122Spanish Oncology Genito-Urinary Group135
Completed
Phase 2
Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate CancerProstate CancerNCT01620593The University of Texas Health Science Center at San Antonio41
Completed
Not Applicable
Transmurale zorg Prostaatkanker, van diagnose tot en met nazorgProstate cancer, transmural care, decision aid, SDM, Follow-up care, Substitution, Family doctors or General practitioners, Prostaatkanker, Keuzehulp, Samenwerking tussen eerste lijn en tweede lijn.NL-OMON22953Initiator: Catharina Wilhelmina Hospital (CWZ)NijmegenPrimary Sponsor/Performer: Radboud University Nijmegen Medical centerOther performers: CWZ in Nijmegen, Maashospital Pantein in Boxmeer200